<DOC>
	<DOC>NCT00461617</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.</brief_summary>
	<brief_title>Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy Type 1 diabetes patients Patients who require treatment with insulin Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy) Patients with severe ketosis, diabetic coma or precoma Patients complicated with severe hepatic diseases Patients complicated with severe renal diseases Patients complicated with severe hypertension Patients complicated with severe cardiac disease Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>diabetes</keyword>
	<keyword>rapid and short acting insulin secretagogue</keyword>
	<keyword>Î±-glucosidase inhibitor</keyword>
	<keyword>HbA1C</keyword>
	<keyword>insulin</keyword>
</DOC>